{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:24:42Z","timestamp":1793316282371,"version":"4.5.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006641","name":"Cure Brain Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006641","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001102","name":"Cancer Council NSW","doi-asserted-by":"publisher","award":["RG 16-13"],"award-info":[{"award-number":["RG 16-13"]}],"id":[{"id":"10.13039\/501100001102","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AbbVie Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Temozolomide offers minimal benefit in patients with glioblastoma with unmethylated O6-methylguanine-DNA methyltransferase (MGMT) promoter status, hence, the need for novel therapies. This study evaluated whether veliparib, a brain-penetrant poly(ADP-ribose) polymerase (PARP) inhibitor, acts synergistically with radiation and temozolomide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>VERTU was a multicenter 2:1 randomized phase II trial in patients with newly diagnosed glioblastoma and MGMT-unmethylated promotor status. The experimental arm consisted of veliparib and radiotherapy, followed by adjuvant veliparib and temozolomide. The standard arm consisted of concurrent temozolomide and radiotherapy, followed by adjuvant temozolomide. The primary objective was to extend the progression-free survival rate at six months (PFS-6m) in the experimental arm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 125 participants were enrolled, with 84 in the experimental arm and 41 in the standard arm. The median age was 61 years, 70% were male, 59% had Eastern Cooperative Oncology Group (ECOG) performance status of 0, and 87% underwent macroscopic resection. PFS-6m was 46% (95% confidence interval [CI]: 36%-57%) in the experimental arm and 31% (95% CI: 18%-46%) in the standard arm. Median overall survival was 12.7 months (95% CI: 11.4-14.5 months) in the experimental arm and 12.8 months (95% CI: 9.5-15.8 months) in the standard arm. The most common grade 3-4 adverse events were thrombocytopenia and neutropenia, with no new safety signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The veliparib-containing regimen was feasible and well tolerated. However, there was insufficient evidence of clinical benefit in this population. Further information from correlative translational work and other trials of PARP inhibitors in glioblastoma are still awaited.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noab111","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T16:16:05Z","timestamp":1620317765000},"page":"1736-1749","source":"Crossref","is-referenced-by-count":98,"title":["A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated\n                    <i>MGMT<\/i>\n                    glioblastoma: the VERTU study"],"prefix":"10.1093","volume":"23","author":[{"given":"Hao-Wen","family":"Sim","sequence":"first","affiliation":[{"name":"NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia"},{"name":"St Vincent\u2019s Clinical School, University of New South Wales, Sydney, Australia"},{"name":"Department of Medical Oncology, The Kinghorn Cancer Centre, Sydney, Australia"},{"name":"Department of Medical Oncology, Chris O\u2019Brien Lifehouse, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerrie L","family":"McDonald","sequence":"additional","affiliation":[{"name":"Cure Brain Cancer Neuro-Oncology Lab, University of New South Wales, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarnie","family":"Lwin","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Queensland, Brisbane, Australia"},{"name":"Department of Medical Oncology, Royal Brisbane and Women\u2019s Hospital, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth H","family":"Barnes","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia"},{"name":"Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C","family":"Foote","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Queensland, Brisbane, Australia"},{"name":"Department of Radiation Oncology, Princess Alexandra Hospital, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eng-Siew","family":"Koh","sequence":"additional","affiliation":[{"name":"South Western Sydney Clinical School, University of New South Wales, Sydney, Australia"},{"name":"Ingham Institute for Applied Medical Research, Sydney, Australia"},{"name":"Department of Radiation Oncology, Liverpool Hospital, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Back","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Royal North Shore Hospital, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik P","family":"Sulman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, NYU Grossman School of Medicine and Brain and Spine Tumors, New York, New York, USA"},{"name":"Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E","family":"Buckland","sequence":"additional","affiliation":[{"name":"Neuropathology Department, Royal Prince Alfred Hospital, Sydney, Australia"},{"name":"Brain and Mind Centre, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Fisher","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Leonard","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merryn","family":"Hall","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia"},{"name":"Duke University School of Medicine, Duke University, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Ashley","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine, Duke University, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Yip","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Simes","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia"},{"name":"Department of Medical Oncology, Chris O\u2019Brien Lifehouse, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3249-9849","authenticated-orcid":false,"given":"Mustafa","family":"Khasraw","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"issue":"4","key":"2021100111114510200_CIT0001","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3322\/caac.21613","article-title":"Management of glioblastoma: state of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J Clin."},{"issue":"8","key":"2021100111114510200_CIT0002","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol."},{"key":"2021100111114510200_CIT0003","article-title":"Management of glioblastoma: an Australian perspective","author":"Sim","year":"2020","journal-title":"Chin Clin Oncol."},{"issue":"10","key":"2021100111114510200_CIT0004","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"5","key":"2021100111114510200_CIT0005","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"issue":"9","key":"2021100111114510200_CIT0006","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","article-title":"ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models","volume":"13","author":"Donawho","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2021100111114510200_CIT0007","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv369","article-title":"Delineation of MGMT hypermethylation as a biomarker for veliparib-mediated temozolomide-sensitizing therapy of glioblastoma","volume":"108","author":"Gupta","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2021100111114510200_CIT0008","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1748-717X-8-65","article-title":"Evaluation of poly(ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma","volume":"8","author":"Barazzuol","year":"2013","journal-title":"Radiat Oncol."},{"issue":"2","key":"2021100111114510200_CIT0009","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1158\/1535-7163.MCT-08-0854","article-title":"Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines","volume":"8","author":"Clarke","year":"2009","journal-title":"Mol Cancer Ther."},{"key":"2021100111114510200_CIT0010","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1158\/1538-7445.AM2014-3777","article-title":"Combining veliparib (ABT-888) with temozolomide shows strong synergy when treating temozolomide-resistant and recurrent GBM cell lines","volume":"74","author":"McDonald","year":"2014","journal-title":"Cancer Res."},{"issue":"1","key":"2021100111114510200_CIT0011","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12967-017-1164-1","article-title":"Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma","volume":"15","author":"Jue","year":"2017","journal-title":"J Transl Med."},{"issue":"13","key":"2021100111114510200_CIT0012","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1158\/0008-5472.CAN-09-4295","article-title":"PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors","volume":"70","author":"McEllin","year":"2010","journal-title":"Cancer Res."},{"issue":"10","key":"2021100111114510200_CIT0013","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1158\/1078-0432.CCR-14-0084","article-title":"ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy","volume":"20","author":"Lin","year":"2014","journal-title":"Clin Cancer Res."},{"key":"2021100111114510200_CIT0014","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fonc.2018.00670","article-title":"PARP inhibitors for sensitization of alkylation chemotherapy in glioblastoma: impact of blood-brain barrier and molecular heterogeneity","volume":"8","author":"Gupta","year":"2018","journal-title":"Front Oncol."},{"issue":"2","key":"2021100111114510200_CIT0015","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-015-1733-1","article-title":"Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study","volume":"122","author":"Mehta","year":"2015","journal-title":"J Neurooncol."},{"issue":"6","key":"2021100111114510200_CIT0016","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2468-1253(17)30012-2","article-title":"Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study","volume":"2","author":"Czito","year":"2017","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"11","key":"2021100111114510200_CIT0017","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1002\/cncr.31309","article-title":"A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer","volume":"124","author":"Pishvaian","year":"2018","journal-title":"Cancer."},{"issue":"1","key":"2021100111114510200_CIT0018","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/annonc\/mdx505","article-title":"Veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in patients with BRCA1\/2 locally recurrent\/metastatic breast cancer: randomized phase II study","volume":"29","author":"Han","year":"2018","journal-title":"Ann Oncol."},{"key":"2021100111114510200_CIT0019","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1200\/jco.2013.31.15_suppl.2065","article-title":"Phase I adult brain tumor consortium trial of ABT-888 (veliparib), temozolomide, and radiotherapy for newly diagnosed glioblastoma multiforme including pharmacokinetic data","volume":"31","author":"Kleinberg","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021100111114510200_CIT0020","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ejca.2012.08.012","article-title":"The T genotype of the MGMT C&gt;T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients","volume":"49","author":"McDonald","year":"2013","journal-title":"Eur J Cancer."},{"issue":"11","key":"2021100111114510200_CIT0021","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol."},{"issue":"5","key":"2021100111114510200_CIT0022","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst."},{"key":"2021100111114510200_CIT0023","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0959-8049(01)00448-8","article-title":"Quality of life research within the EORTC: the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer","volume":"38","author":"Fayers","year":"2002","journal-title":"Eur J Cancer."},{"issue":"6","key":"2021100111114510200_CIT0024","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ejca.2010.01.012","article-title":"An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients","volume":"46","author":"Taphoorn","year":"2010","journal-title":"Eur J Cancer."},{"key":"2021100111114510200_CIT0025","volume-title":"EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"1995"},{"issue":"19","key":"2021100111114510200_CIT0026","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1200\/JCO.2014.60.3217","article-title":"Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma","volume":"33","author":"Taphoorn","year":"2015","journal-title":"J Clin Oncol."},{"issue":"10","key":"2021100111114510200_CIT0027","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.ejca.2015.03.025","article-title":"The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial","volume":"51","author":"Dirven","year":"2015","journal-title":"Eur J Cancer."},{"issue":"1","key":"2021100111114510200_CIT0028","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol."},{"issue":"3","key":"2021100111114510200_CIT0029","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s11060-017-2479-8","article-title":"Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma","volume":"133","author":"Field","year":"2017","journal-title":"J Neurooncol."},{"issue":"32","key":"2021100111114510200_CIT0030","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J Clin Oncol."},{"issue":"2","key":"2021100111114510200_CIT0031","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/neuonc\/noy132","article-title":"MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges","volume":"21","author":"Mansouri","year":"2019","journal-title":"Neuro Oncol."},{"issue":"2","key":"2021100111114510200_CIT0032","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","article-title":"Modified criteria for radiographic response assessment in glioblastoma clinical trials","volume":"14","author":"Ellingson","year":"2017","journal-title":"Neurotherapeutics."},{"issue":"1","key":"2021100111114510200_CIT0033","article-title":"Current status of PET imaging in neuro-oncology","volume":"1","author":"Galldiks","year":"2019","journal-title":"Neurooncol Adv."},{"key":"2021100111114510200_CIT0034","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.6732","article-title":"The role of temozolomide in patients with newly diagnosed wild-type IDH, unmethylated MGMTp glioblastoma during the COVID-19 pandemic.","author":"Kamson","year":"2021","journal-title":"JAMA Oncol."},{"issue":"10","key":"2021100111114510200_CIT0035","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med."},{"issue":"11","key":"2021100111114510200_CIT0036","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N Engl J Med."},{"issue":"375","key":"2021100111114510200_CIT0037","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci Transl Med."},{"issue":"2","key":"2021100111114510200_CIT0038","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/cancers12020394","article-title":"PARP inhibitors as therapeutics: beyond modulation of PARylation","volume":"12","author":"Min","year":"2020","journal-title":"Cancers (Basel)."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noab111\/38588412\/noab111.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/10\/1736\/40493789\/noab111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/10\/1736\/40493789\/noab111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T09:55:54Z","timestamp":1672048554000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/23\/10\/1736\/6275307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,5,13]]},"published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noab111","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,5,13]]}}}